Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine

Human Psychopharmacology

Volumn 26, Issue 3, 2011, Pages 242-251

  Sheehan, David V ^a   Chokka, Pratap R ^b   Granger, Renee E ^b   Walton, Richard J ^c   Raskin, Joel ^c   Sagman, Doron ^d,e  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ELI LILLY AUSTRALIA PTY LTD   (Australia)

^d ELI LILLY AND COMPANY   (United States)

^e Clinical Research   (Canada)

Author keywords

Anxiety; Duloxetine; Function; Major depressive disorder; Mood; Pain

Indexed keywords

CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADULT; ANXIETY; ARTICLE; BRIEF PAIN INVENTORY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; MAIER SCORE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD; OPTIMAL DRUG DOSE; PAIN; PRIORITY JOURNAL; RATING SCALE; REMISSION; SCORING SYSTEM; SHEEHAN DISABILITY SCALE; TREATMENT OUTCOME;

ADULT; DEPRESSIVE DISORDER, MAJOR; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TREATMENT OUTCOME;

EID: 80051800924     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1199     Document Type: Article

References (28)

1. Bair MJ, Robinson RL, Eckert GJ, Stang PE, Croghan TW, Kroenke K. 2004. Impact of pain on depression treatment response in primary care. Psychosom Med 66: 17-22. (Pubitemid 38146528)
2. Brecht S, Courtecuisse C, Debieuvre C, et al. 2007. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry 68: 1707-1716. (Pubitemid 350247500)
3. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. 2001. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25: 871-880. (Pubitemid 34031892)
4. Cleeland CS, Ryan KM. 1994. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23: 129-138.
5. Demyttenaere K, Bonnewyn A, Bruffaerts R, Brugha T, De Graaf R, Alonso J. 2006. Comorbid painful physical symptoms and depression: prevalence, work loss, and help seeking. J Affect Disord 92: 185-193.
6. Endicott J, Russell JM, Raskin J, et al. 2007. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies. J Clin Psychiatry 68: 518-524. (Pubitemid 46663033)
7. Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ. 2000. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 34: 3-10. (Pubitemid 30006935)
8. Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM. 2004. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 65: 521-530.
9. Fava M, Wiltse C, Walker D, Brecht S, Chen A, Perahia D. 2009. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder. J Affect Disord 113: 263-271.
10. Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA. 2004. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 45: 17-28. (Pubitemid 38082504)
11. Johnson JB, Omland KS. 2004. Model selection in ecology and evolution. Trends Ecol Evol 19: 101-108. (Pubitemid 38105895)
12. Judd LL, Akiskal HS, Maser JD, et al. 1998. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 50: 97-108. (Pubitemid 28551779)
13. Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. 1997. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 27: 93-105. (Pubitemid 27407503)
14. Leuchter AF, Husain MM, Cook IA, et al. 2010. Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. Psychol Med 40: 239-251.
15. Maier W, Phillip M. 1985. Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry 18: 114-115. (Pubitemid 15137667)
16. Muñoz RA, McBride ME, Brnabic AJ, et al. 2005. Major depressive disorder in Latin America: the relationship between depression severity, painful somatic symptoms, and quality of life. J Affect Disord 86: 93-98. (Pubitemid 40487965)
17. Nierenberg AA, Petersen TJ, Alpert JE. 2003. Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy. J Clin Psychiatry 64(Suppl. 15): 13-17. (Pubitemid 37464492)
18. Perahia DG, Quail D, Desaiah D, Corruble E, Fava M. 2008. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. J Clin Psychiatry 69: 95-105. (Pubitemid 351282002)
19. Perahia DG, Quail D, Desaiah D, Montejo AL, Schatzberg AF. 2009. Switching to duloxetine in selective serotonin reuptake inhibitor nonand partial-responders: effects on painful physical symptoms of depression. J Psychiatr Res 43: 512-518.
20. Pollack MH, Endicott J, Liebowitz M, et al. 2008. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res 42: 1042-1049.
21. Rush AJ, Trivedi MH, Wisniewski SR, et al. 2006. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163: 1905-1917. (Pubitemid 44807782)
22. Sagman D, McIntosh D, Lee M, et al. 2011. Attributes of response in depressed patients switched to treatment with duloxetine. Int J Clin Pract 65: 73-81.
23. Sheehan DV, Harnett-Sheehan K, Raj BA. 1996. The measurement of disability. Int Clin Psychopharmacol 11(Suppl. 3): 89-95. (Pubitemid 26373761)
24. Sheehan DV, Meyers AL, Prakash A, et al. 2008. The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. Curr Med Res Opin 24: 2457-2466.
25. Sheehan KH, Sheehan DV. 2008. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol 23: 70-83. (Pubitemid 351317279)
26. Wise TN, Fishbain DA, Holder-Perkins V. 2007. Painful physical symptoms in depression: a clinical challenge. Pain Med 8(Suppl. 2): S75-S82. (Pubitemid 47288513)
27. Wise TN, Meyers AL, Desaiah D, Mallinckrodt CH, Robinson MJ, Kajdasz DK. 2008. The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: a post hoc analysis of 2 trials. Prim Care Companion J Clin Psychiatry 10: 270-275.
28. Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP. 2007. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Depress Anxiety 24: 41-52. (Pubitemid 46278679)